Current Treatment and Application of Hyperthermia for Squamous Cell Carcinoma of the Esophagus

M. Morita, M. Ikebe, Masaki Kagawa, Y. Nakaji, M. Sugiyama, D. Yoshida, M. Ota, T. Iguchi, K. Sugimachi, N. Kunitake, H. Saeki, E. Oki, S. Ohga, Y. Toh, Y. Maehara
{"title":"Current Treatment and Application of Hyperthermia for Squamous Cell Carcinoma of the Esophagus","authors":"M. Morita, M. Ikebe, Masaki Kagawa, Y. Nakaji, M. Sugiyama, D. Yoshida, M. Ota, T. Iguchi, K. Sugimachi, N. Kunitake, H. Saeki, E. Oki, S. Ohga, Y. Toh, Y. Maehara","doi":"10.3191/THERMALMED.33.63","DOIUrl":null,"url":null,"abstract":"Squamous cell carcinoma of the esophagus (ESCC) is a fairly aggressive disease with a poor prognosis. Surgical resection has been the gold standard of treatment for localized ESCC. However, this carcinoma is fairly sensitive to radiation, as well as chemotherapeutic agents such as cisplatin and 5-fluorouracil. Based on clinical trials conducted mainly by the Japan Clinical Oncology Group (JCOG), preoperative chemotherapy is regarded as the standard treatment for resectable ESCC in Japan. We have applied hyperthermia to ESCC mainly as a preoperative treatment associated with chemoradiotherapy since it has been experimentally proven to enhance the anti-tumor effects of chemotherapeutic agents and irradiation. The long-term survival as well as histological effectiveness was reported to be better in patients who received preoperative hyperthermochemoradiotherapy (HCR) than in those who received preoperative chemoradiotherapy (CRT). Definitive CRT is frequently performed even for resectable ESCC, and salvage treatment for either remnant or recurrent diseases remains an important clinical problem. We have applied hyperthermia simultaneously with chemotherapy as a salvage treatment for such patients, and complete response as well as stable disease was achieved in several patients. Hyperthermia is a promising modality as a salvage treatment and has recently been incorporated into regimens including taxanes. Potential enhancement of hyperthermia with certain drugs should be experimentally evaluated, and the clinical application of Hyperthermia for esophageal cancer ・ M. Morita et al. 63 ― ― Received 6 July, 2017, Accepted 28 August, 2017: This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sport, Science and Technology of Japan and the Fujii Setsuro Memorial Foundation. *Corresponding author: Tel, +81-92-541-3231; Fax, +81-92-542-8503; e-mail, masarum@nk-cc.go.jp doi: 10.3191/thermalmed.33.63 ©2017 Japanese Society for Thermal Medicine hyperthermia may be warranted with other newly-developed regimens.","PeriodicalId":23299,"journal":{"name":"Thermal Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thermal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3191/THERMALMED.33.63","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Squamous cell carcinoma of the esophagus (ESCC) is a fairly aggressive disease with a poor prognosis. Surgical resection has been the gold standard of treatment for localized ESCC. However, this carcinoma is fairly sensitive to radiation, as well as chemotherapeutic agents such as cisplatin and 5-fluorouracil. Based on clinical trials conducted mainly by the Japan Clinical Oncology Group (JCOG), preoperative chemotherapy is regarded as the standard treatment for resectable ESCC in Japan. We have applied hyperthermia to ESCC mainly as a preoperative treatment associated with chemoradiotherapy since it has been experimentally proven to enhance the anti-tumor effects of chemotherapeutic agents and irradiation. The long-term survival as well as histological effectiveness was reported to be better in patients who received preoperative hyperthermochemoradiotherapy (HCR) than in those who received preoperative chemoradiotherapy (CRT). Definitive CRT is frequently performed even for resectable ESCC, and salvage treatment for either remnant or recurrent diseases remains an important clinical problem. We have applied hyperthermia simultaneously with chemotherapy as a salvage treatment for such patients, and complete response as well as stable disease was achieved in several patients. Hyperthermia is a promising modality as a salvage treatment and has recently been incorporated into regimens including taxanes. Potential enhancement of hyperthermia with certain drugs should be experimentally evaluated, and the clinical application of Hyperthermia for esophageal cancer ・ M. Morita et al. 63 ― ― Received 6 July, 2017, Accepted 28 August, 2017: This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sport, Science and Technology of Japan and the Fujii Setsuro Memorial Foundation. *Corresponding author: Tel, +81-92-541-3231; Fax, +81-92-542-8503; e-mail, masarum@nk-cc.go.jp doi: 10.3191/thermalmed.33.63 ©2017 Japanese Society for Thermal Medicine hyperthermia may be warranted with other newly-developed regimens.
热疗治疗食管鳞状细胞癌的现状及应用
食管鳞状细胞癌(ESCC)是一种侵袭性很强的疾病,预后较差。手术切除一直是治疗局限性ESCC的金标准。然而,这种癌对放射以及化疗药物如顺铂和5-氟尿嘧啶相当敏感。根据主要由日本临床肿瘤小组(JCOG)开展的临床试验,术前化疗在日本被视为可切除ESCC的标准治疗方法。我们将热疗应用于ESCC,主要是作为术前与放化疗相关的治疗,因为实验证明热疗可以增强化疗药物和放疗的抗肿瘤作用。据报道,术前接受高温放化疗(HCR)的患者的长期生存和组织学疗效优于术前接受放化疗(CRT)的患者。即使对于可切除的ESCC,也经常进行明确的CRT,对于残余或复发疾病的抢救治疗仍然是重要的临床问题。我们将热疗与化疗同时应用于此类患者的抢救治疗,有几例患者达到完全缓解和病情稳定。热疗是一种很有前途的救助性治疗方式,最近已被纳入包括紫杉烷在内的治疗方案。应实验评估某些药物对热疗的潜在增强作用,以及热疗在食管癌中的临床应用·M. Morita等。63 - - 2017年7月6日收到,2017年8月28日接受:这项工作得到了日本教育、文化、体育、科学技术省和藤井Setsuro纪念基金会的部分资助。*通讯作者:电话:+81-92-541-3231;传真+ 81-92-542-8503;e-mail, masarum@nk-cc.go.jp doi: 10.3191/thermalmed.33.63©2017日本热医学学会热疗可能与其他新开发的方案一起得到保证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信